Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Stopped This study was withdrawn due to a strategic business decision; no patients were enrolled.

Conditions

• NSCLC

Interventions

• DRUG: Tipifarnib
• DRUG: Osimertinib

Sponsor

Kura Oncology, Inc.